Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan;91(1):101-19.
doi: 10.1016/j.mayocp.2015.11.007.

Multiple Myeloma: Diagnosis and Treatment

S Vincent Rajkumar  1 , Shaji Kumar  2
Affiliations
Review

Multiple Myeloma: Diagnosis and Treatment

S Vincent Rajkumar et al. Mayo Clin Proc. 2016 Jan.

Abstract

The diagnosis and treatment of multiple myeloma has changed dramatically in the past decade. The disease definition has been updated to include highly specific biomarkers in addition to established markers of end-organ damage. The staging system has been revised to combine both measures of tumor burden and disease biology. Advances in therapy have resulted in a marked improvement in overall survival. New drugs introduced in the past few years include carfilzomib, pomalidomide, panobinostat, ixazomib, elotuzumab, and daratumumab. In this review, we outline the current approach to the diagnosis, prognosis, and management of multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

Authorship Contributions and Disclosure of Conflicts of Interest SVR declares no conflict of interest. SK has obtained research support for clinical trials from Celgene, Millennium, Novartis, Janssen, Sanofi.

Figures

Figure 1
Figure 1
Approach to the treatment of newly diagnosed multiple myeloma Abbreviations: VRD, bortezomib, lenalidomide, dexamethasone; KRD, carfilzomib, lenalidomide, dexamethasone; Rd, lenalidomide plus dexamethasone; VCD, bortezomib, cyclophosphamide, dexamethasone; ASCT, autologous stem cell transplantation; CR, complete response; VGPR, very good partial response.
See this image and copyright information in PMC

References

    1. Rajkumar SV, Dimopoulos MA, Palumbo A, et al. International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. Lancet Oncol. 2014;15:e538–548. - PubMed
    1. Rajkumar SV. Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:998–1009. - PubMed
    1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ., 3rd Incidence of multiple myeloma in Olmsted County, Minnesota: Trend over 6 decades. Cancer. 2004;101:2667–2674. - PubMed
    1. Landgren O, Gridley G, Turesson I, et al. Risk of monoclonal gammopathy of undetermined significance (MGUS) and subsequent multiple myeloma among African American and white veterans in the United States. Blood. 2006;107:904–906. - PMC - PubMed
    1. Landgren O, Graubard BI, Katzmann JA, et al. Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the national health and nutritional examination survey. Leukemia. 2014;28:1537–1542. - PMC - PubMed

Publication types

MeSH terms

Substances